Swati Dhar currently serves as a Clinical Scientist specializing in Cardiovascular and Respiratory studies at Parexel, where she leverages her extensive expertise in bioanalytical and biomarker study design to drive innovative clinical research initiatives. With a robust background in managing end-to-end processes from non-clinical to...
Swati Dhar currently serves as a Clinical Scientist specializing in Cardiovascular and Respiratory studies at Parexel, where she leverages her extensive expertise in bioanalytical and biomarker study design to drive innovative clinical research initiatives. With a robust background in managing end-to-end processes from non-clinical to early clinical development, Swati plays a pivotal role in supporting Phase 3 studies, particularly focusing on medical data reviewing and efficacy analysis. Her proficiency in Good Clinical Practice (GCP) ensures that all studies adhere to the highest regulatory standards, fostering trust and integrity in the data collected.
Swati’s work involves cross-functional collaboration with clinical operations, regulatory affairs, and clinical quality teams, as well as managing relationships with CROs and vendors. This collaborative approach not only enhances the efficiency of study execution but also ensures that all stakeholders are aligned with the project goals. Her technical acumen is complemented by her skills in biomarker discovery and development, where she employs advanced analytical tools such as IBM SPSS and GraphPad Prism to interpret complex data sets and derive actionable insights.
In her role, Swati is dedicated to advancing the understanding of cardiovascular and respiratory diseases through rigorous scientific inquiry and innovative study designs. Her commitment to excellence and her ability to navigate the complexities of clinical research make her a valuable asset to Parexel and the broader clinical research community. As she continues to contribute to key projects, her insights and leadership will undoubtedly play a crucial role in shaping the future of clinical trials in these critical therapeutic areas.
